Raphael Schmitt

Mr. Raphael Schmitt

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
MSMarkus G. Seidel
Markus G. Seidel
GKGerhard Kindle
Gerhard Kindle
BGBenjamin Gathmann
Benjamin Gathmann
IQIsabella Quinti
Isabella Quinti
MBMatthew Buckland
Matthew Buckland
SZShen-Yin Zhang
Shen-Yin Zhang

16 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMaria Elena Maccari
Maria Elena Maccari
Hassan AbolhassaniHassan Abolhassani
Hassan Abolhassani
AAAsghar Aghamohammadi
Asghar Aghamohammadi
AAAlessandro Aiuti
Alessandro Aiuti
OAOlga Aleinikova
Olga Aleinikova
SEStephan Ehl
Stephan Ehl
Activated phosphoinositide 3-kinase (PI3K) δ Syndrome (APDS), caused by autosomal dominant mutations in PIK3CD (APDS1) or PIK3R1 (APDS2), is a heterogeneous primary immunodeficiency. While initial cohort-descriptions summarized the spectrum of clinical and immunological manifestations, questions about long-term disease evolution and response to therapy remain. The prospective European Society for Immunodeficiencies (ESID)-APDS registry aims to characterize the disease course, identify outcome predictors, and evaluate treatment responses. So far, 77 patients have been recruited (51 APDS1, 26 APDS2). Analysis of disease evolution in the first 68 patients pinpoints the early occurrence of recurrent respiratory infections followed by chronic lymphoproliferation, gastrointestinal manifestations, and cytopenias. Although most manifestations occur by age 15, adult-onset and asymptomatic courses were documented. Bronchiectasis was observed in 24/40 APDS1 patients who received a CT-scan compared with 4/15 APDS2 patients. By age 20, half of the patients had received at least one immunosuppressant, but 2–3 lines of immunosuppressive therapy were not unusual before age 10. Response to rapamycin was rated by physician visual analog scale as good in 10, moderate in 9, and poor in 7. Lymphoproliferation showed the best response (8 complete, 11 partial, 6 no remission), while bowel inflammation (3 complete, 3 partial, 9 no remission) and cytopenia (3 complete, 2 partial, 9 no remission) responded less well. Hence, non-lymphoproliferative manifestations should be a key target for novel therapies. This report from the ESID-APDS registry provides comprehensive baseline documentation for a growing cohort that will be followed prospectively to establish prognostic factors and identify patients for treatment studies.

19 July 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
SESabine M El-Helou
Sabine M El-Helou
ABAnika-Kerstin Biegner
Anika-Kerstin Biegner
SBSebastian Bode
Sebastian Bode
SEStephan R Ehl
Stephan R Ehl
MHMaximilian Heeg
Maximilian Heeg
BGBodo Grimbacher
Bodo Grimbacher
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.

28 June 2023 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MMMaria Elena Maccari
Maria Elena Maccari
MWMartin Wolkewitz
Martin Wolkewitz
CSCharlotte Schwab
Charlotte Schwab
TLTiziana Lorenzini
Tiziana Lorenzini
JLJennifer W. Leiding
Jennifer W. Leiding
OSOksana A. Shvets
Oksana A. Shvets

1 January 2024
Verified
Conference Paper
Open access
PDF file
Raphael SchmittRaphael Schmitt
Raphael Schmitt
JFJohann Frei
Johann Frei
FTFabian Thomczyk
Fabian Thomczyk
HHHenry He
Henry He
PTPatric Tippmann
Patric Tippmann
MBMartin Boeker
Martin Boeker
Raphael Scheible, Johann Frei, Fabian Thomczyk, Henry He, Patric Tippmann, Jochen Knaus, Victor Jaravine, Frank Kramer, Martin Boeker. Proceedings of the 2024 Conference on Empirical Methods in Natural Language Processing. 2024.

2 July 2019 in Bioinformatics
Verified
Journal Article
Open access
PDF file
Raphael SchmittRaphael Schmitt
Raphael Schmitt
SRStephan Rusch
Stephan Rusch
DGDavid Guzman
David Guzman
NMNizar Mahlaoui
Nizar Mahlaoui
SEStephan Ehl
Stephan Ehl
GKGerhard Kindle
Gerhard Kindle
Primary Immunodeficiencies (PIDs) belong to the group of rare diseases. The European Society for Immunodeficiencies (ESID) operates an international research database application for continuous long-term documentation of patient data. The system is a web application which runs in a standard browser. Therefore, the system is easy to access from any location. Technically, the system is based on Gails backed by MariaDB with high standard security features to comply with the demands of a modern research platform. The ESID Online Database is accessible via the official website: https://esid.org/Working-Parties/Registry-Working-Party/ESID-Registry. A demo system is available via: https://cci-esid-reg-demo-app.uniklinik-freiburg.de/EERS with user demouser and password Demo-2019.